{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T19:19:47Z","timestamp":1771528787749,"version":"3.50.1"},"reference-count":44,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100007705","name":"Astellas | Astellas Pharma Global Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Invasive pulmonary aspergillosis (IPA) is an important cause of morbidity and mortality in immunocompromised patients. We hypothesized that simultaneous inhibition of biosynthesis of ergosterol in the fungal cell membrane and (1\u21923)-\u03b2-\n            <jats:sc>d<\/jats:sc>\n            -glucan in the cell wall, respectively, by the antifungal triazole isavuconazole (ISA) and the echinocandin micafungin (MFG) may result in improved outcomes in experimental IPA in persistently neutropenic rabbits. Treatments included ISA at 20 mg\/kg of body weight\/day (ISA20), 40 mg\/kg\/day (ISA40), and 60 mg\/kg\/day (ISA60); MFG at 2 mg\/kg\/day (MFG2); combinations of ISA20 and MFG2, ISA40 and MFG2, and ISA60 and MFG2; and no treatment (untreated controls [UC]). The galactomannan index (GMI) and (1\u21923)-\u03b2-\n            <jats:sc>d<\/jats:sc>\n            -glucan levels in serum were measured. The residual fungal burden (number of CFU per gram) was significantly reduced in ISA20-, ISA40-, ISA60-, ISA20-MFG2-, ISA40-MFG2-, and ISA60-MFG2-treated rabbits compared with that in MFG2-treated or UC rabbits (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.01). Measures of organism-mediated pulmonary injury, lung weights, and pulmonary infarct score were lower in ISA40-MFG2-treated rabbits than in rabbits treated with ISA40 or MFG2 alone (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.01). Survival was prolonged in ISA40-MFG2-treated rabbits in comparison to those treated with ISA40 or MFG2 alone (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.01). These outcome variables correlated directly with significant declines in GMI and serum (1\u21923)-\u03b2-\n            <jats:sc>d<\/jats:sc>\n            -glucan levels during therapy. The GMI correlated with measures of organism-mediated pulmonary injury, lung weights (\n            <jats:italic>r<\/jats:italic>\n            = 0.764;\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001), and pulmonary infarct score (\n            <jats:italic>r<\/jats:italic>\n            = 0.911;\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001). In summary, rabbits receiving combination therapy with isavuconazole and micafungin demonstrated a significant dose-dependent reduction in the residual fungal burden, decreased pulmonary injury, prolonged survival, a lower GMI, and lower serum (1\u21923)-\u03b2-\n            <jats:sc>d<\/jats:sc>\n            -glucan levels in comparison to rabbits receiving isavuconazole or micafungin as a single agent.\n          <\/jats:p>","DOI":"10.1128\/aac.00305-17","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T00:25:30Z","timestamp":1499732730000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":21,"title":["Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis"],"prefix":"10.1128","volume":"61","author":[{"given":"Vidmantas","family":"Petraitis","sequence":"first","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"},{"name":"Institute of Infectious Disease and Pathogenic Microbiology, Prienai, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruta","family":"Petraitiene","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"},{"name":"Institute of Infectious Disease and Pathogenic Microbiology, Prienai, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew W.","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4493-4652","authenticated-orcid":false,"given":"Laura L.","family":"Kovanda","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myo H.","family":"Zaw","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiser","family":"Hussain","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naima","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo Bo W.","family":"Maung","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navjot K.","family":"Sekhon","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William W.","family":"Hope","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"},{"name":"Departments of Pediatrics and Microbiology &amp; Immunology, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/651263"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-206291"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780902718339"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181acd956"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2009.03.008"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03261-14"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7104-6_18"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/375420"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00673-10"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061124"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129022"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myv034"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00329-09"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw098"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myw118"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9509-1"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix198"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/528715"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/528714"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir441"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22863"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2003.tb00034.x"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.061562898"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.15.34"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2012.683859"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ571"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04055-14"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00636-13"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00863-13"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2015.04.008"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01355-13"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2015.990382"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02665-15"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1857-1869.2002"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01159-9"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072-1439.2014.01.18"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.7326\/M13-2508"},{"key":"e_1_3_2_40_2","volume-title":"Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard,2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute,Wayne, PA.","edition":"2"},{"key":"e_1_3_2_41_2","volume-title":"Guide for the care and use of laboratory animals","author":"National Research Council","year":"2011","unstructured":"National Research Council. 2011. Guide for the care and use of laboratory animals,8th ed. National Academies Press,Washington, DC.","edition":"8"},{"key":"e_1_3_2_42_2","first-page":"467","article-title":"Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits","volume":"38","author":"Walsh TJ","year":"1988","unstructured":"Walsh TJ BacherJPizzoPA. 1988. Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci38:467\u2013471.","journal-title":"Lab Anim Sci"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.857-869.2001"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.60.6.2237-2245.1992"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00674-08"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00305-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00305-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:53:31Z","timestamp":1645476811000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00305-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1128\/AAC.00305-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.00305-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"2017-02-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00305-17"}}